Aerosol Delivery Devices Market

Market Overview:

The global aerosol delivery devices market size reached US$ 44.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 63.3 Billion by 2028, exhibiting a growth rate (CAGR) of 5.4% during 2023-2028.

Aerosol delivery devices are used in drug delivery and treating respiratory disorders, such as asthma, obstructive lung diseases, cystic fibrosis, pulmonary arterial hypertension, infectious pulmonary. They lower dosage requirements, reduce systemic adverse effects and improve the ability of patients to self-administer medication. Some of the commonly available aerosol delivery devices are pressurized metered-dose inhalers, nebulizers, and valved holder chambers. At present, smart aerosol drug delivery devices are used in non-respiratory conditions, such as diabetes, analgesia, thyroid disorders, and genetic diseases, due to the advent of novel macromolecular medications.

Aerosol Delivery Devices Market Trends:

The global outbreak of the coronavirus disease (COVID-19) that leads to acute respiratory infections among patients represents one of the key factors driving the need for aerosol delivery devices. These devices assist in treating obstructive airway diseases at home and in healthcare settings. Apart from this, the rising prevalence of chronic respiratory infections due to surging air pollution levels, allergens and occupational risks, and the increasing number of individuals who smoke tobacco and drink is propelling the market growth. Moreover, a considerable rise in the geriatric population, which is more vulnerable to developing serious health illnesses, is positively influencing the demand for portable inhalation devices that are convenient and economical. Besides this, market players are developing novel aerosol delivery devices that help treat chronic inflammation and infection in the lungs and improve airway clearance in patients with cystic fibrosis (CF). Furthermore, they are offering mini ultrasonic nebulizers and inhalers through e-commerce channels that have automatic memory and are easy to use while traveling. This, in confluence with the escalating demand for personalized drug therapy and the increasing use of online channels for purchasing medical supplies, is driving the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global aerosol delivery devices market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, application and distribution channel.

Breakup by Product:

• Dry Powder Inhalers
  • Single Dose Inhalers
  • Multi Dose Inhalers
• Metered Dose Inhalers
  • Conventional Pressurized Inhalers
  • Soft Mist Inhalers
• Nebulizers
  • Jet Nebulizers
  • Ultrasonic Wave Nebulizers
  • Vibrating Mesh Nebulizers
     

Breakup by Application:

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Cystic Fibrosis
• Non-Respiratory Diseases
  • Diabetes
  • Analgesia
  • Parkinson’s Disease
     

Breakup by Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• Online Stores
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Aerogen, GlaxoSmithKline plc, Johnson & Johnson, Koninklijke Philips N.V., Merck & Co. Inc., Metall Zug AG, Recipharm AB (publ), Teva Pharmaceutical Industries Ltd. and Vectura Group plc.

Report Coverage: